Carmustine (FIVB)

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)

Also Known As:

Networked: 2249 relevant articles (210 outcomes, 480 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Brem, Henry: 27 articles (11/2019 - 02/2002)
2.	Gerson, Stanton L: 12 articles (01/2017 - 04/2002)
3.	Friedman, Henry S: 12 articles (08/2009 - 05/2002)
4.	Olivi, Alessandro: 11 articles (08/2015 - 04/2003)
5.	Kumabe, Toshihiro: 10 articles (09/2022 - 11/2013)
6.	Tyler, Betty: 10 articles (10/2021 - 02/2002)
7.	Tyler, Betty M: 9 articles (01/2017 - 11/2002)
8.	Wei, Kuo-Chen: 9 articles (01/2016 - 01/2005)
9.	Finke, Jürgen: 8 articles (08/2016 - 09/2002)
10.	Weingart, Jon D: 8 articles (08/2015 - 03/2003)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1988 - "Among these drugs, only a relatively low dose of BCNU (15-20 mg/kg) was effective in curing most mice (85%) bearing a large, late stage tumor. " 03/01/2015 - "In tumor-bearing animals, BCNU bubbles with FUS showed significant control of tumor progression and improved maximum survival from 26 to 35 days. " 08/01/1985 - "Furthermore, LSA tumor cells that failed to evoke tumor-specific CTL activity in normal mice could induce high CTL activity in BCNU-cured mice. " 09/01/2003 - "dBG, a weak MGMT inactivator in vitro as compared with BG, was markedly more effective than the latter in enhancing the efficacy of BCNU against pancreatic tumor xenografts. " 04/01/1981 - "Treatment with BCNU 1 hour before or 1 day after neutron irradiation proved to be no more effective in proving the survival time of tumor-bearing animals than the drug similarly combined with conventional gamma irradiation."
2.	Glioma (Gliomas) 10/01/2010 - "Randomized phase III trials have shown significant improvement of survival 1, 2, and 3 years after implantation of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for patients with newly diagnosed malignant glioma. " 12/01/2017 - "Finally, carmustine wafer implantation appears to be cost-effective in high-grade glioma patients when performed by an experienced team and when total or subtotal resection can be achieved. " 10/01/2010 - "Combining these techniques significantly improved the delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea to rodent gliomas. " 01/15/1998 - "Treatment with radiation, IFN-a, and BCNU is feasible and effective in patients with high-grade gliomas, although constitutional symptoms from IFN-a are substantial." 01/01/1997 - "Dose escalation of BCNU does not seem beneficial in children with high-grade gliomas."
3.	Glioblastoma (Glioblastoma Multiforme) 01/01/2015 - "The study investigated if intraoperative use of carmustine wafers, particularly in combination with Stupp regimen, is a viable and safe first-line treatment option of glioblastomas. " 04/01/2022 - "An observational retrospective monocentric study was conducted including 122 consecutive adult patients with a newly diagnosed supratentorial glioblastoma who underwent a surgical resection with Carmustine wafer implantation as first line treatment (2005-2018). " 10/01/2017 - "To assess together safety, tolerance and efficacy of Carmustine wafer implantation and of extent of resection for glioblastoma patients in real-life experience. " 01/01/2015 - "The intraoperative use of carmustine wafers in combination with Stupp regimen is a viable first-line treatment option of glioblastomas. " 01/01/2015 - "Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas."
4.	Brain Neoplasms (Brain Tumor) 04/01/2011 - "Anti-EGFR/BCNU-CASLNs demonstrated the properties including an effective delivery to U87MG cells and antiproliferative efficacy against the growth of malignant brain tumors." 10/01/1982 - "This preliminary study was undertaken to identify the combined efficacy of perfluorochemicals (Fluosol-43) and a chemotherapeutic agent (BCNU) in a rat brain tumor model. " 08/01/2004 - "As part of a Pediatric Oncology Group Phase I study, 120 mg/m(2) of O(6)BG was administered i.v. over 1 h, before 1,3-bis(2-chloroethyl)-1-nitrosourea administration in children with recurrent or refractory brain tumors. " 08/27/1999 - "This paper reports the development of three-dimensional simulations to study the effect of various factors on the delivery of 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to brain tumors. " 04/01/1996 - "The aim of our study is to characterize the disturbance induced by repeated BCNU treatments in 12 human brain tumor cell lines in terms of their collective behavior. "
5.	Lymphoma (Lymphomas) 01/01/1984 - "Adoptive transfer of immunity by spleen cells from LSA-lymphoma mice cured by BCNU." 06/01/1976 - "Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group." 08/26/2015 - "Recently, mainly due to the unavailability of carmustine, several novel conditioning protocols have been clinically developed, with the aim of improving the overall outcome by enhancing the anti-lymphoma effect and, at the same time, by reducing short and long-term toxicity. " 02/01/2011 - "BCNU at 300 mg/m(2) in a CBV regimen prior to PBSCT is well tolerated in relapsed or refractory pediatric lymphoma patients. " 12/01/1985 - "Death from RadLV lymphomas which had been initiated in 33 +/- 3 day old C57BL mice by intrathymic injection of RadLV was scored in untreated, BCNU-treated or BCNU and cellular adjuvant treated mice. "

Related Drugs and Biologics

1.	Carmustine (FIVB)
2.	Etoposide (VP 16)
3.	Cyclophosphamide (Cytoxan)
4.	Cytarabine (Cytosar-U)
5.	Melphalan (Alkeran)
6.	Cisplatin (Platino)
7.	Temozolomide (Temodar)
8.	Polymers
9.	Vincristine (Oncovin)
10.	Lomustine (CCNU)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Stem Cell Transplantation
5.	Combination Drug Therapy (Combination Chemotherapy)